TruSight Oncology 500 family is a next-generation sequencing tumor profiling assay that analyzes 523 genes for cancer-related biomarkers with FFPE samples. The assay supports the identification of DNA and RNA variants implicated in various tumor types, including measuring key immunotherapy biomarkers such as tumor mutation burden (TMB) and microsatellite instability (MSI).
This webinar provides an overview of TruSight Oncology 500 portfolio including analysis and is targeted at new users of the workflow. We will also introduce TSO500 ctDNA v2 and illumina cfDNA Enrichment for liquid biopsy.
Speakers:
![]() |
Deresa Lee |
![]() |
Seon Jung Yun |